Freeline Therapeutics Holdings Plc Stock Price, News & Analysis

Freeline Therapeutics (FRLN) presented long-term data from its B-AMAZE trial at the ASH Annual Meeting, showing sustained FIX expression up to 3.5 years post-treatment with FLT180a for hemophilia B. The results suggest potential for normal Factor IX levels with low vector doses. The company has also launched the B-LIEVE trial ahead of schedule, aiming to confirm dosing strategies and supportive immune management for the upcoming Phase 3 trial. Interim data from B-LIEVE is expected in mid-2022.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) announced on December 6, 2021, that it granted stock options to its new Chief Medical Officer, Pamela Foulds, MD, and another employee. The total options issued were 240,000 and 7,200 shares respectively. This grant, compliant with Nasdaq Listing Rule 5635(c)(4), serves as a material inducement for the new hires. The options have an exercise price of $2.38 per share, with a ten-year maximum term and a four-year vesting schedule. Freeline is focused on advanced AAV-mediated gene therapies for severe inherited diseases.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) announced its participation in the Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021. CEO Michael Parini will engage in a Fireside Chat at 3:55 p.m. EST. A webcast will be accessible for 90 days on the Investors section of Freeline’s website. The company focuses on AAV-mediated gene therapies for severe inherited diseases, with ongoing programs in hemophilia B and Fabry disease.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) will participate in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 1:20 p.m. ET. CEO Michael Parini is scheduled for a Fireside Chat. A webcast of this event will be available for 90 days on the Freeline website. Additionally, senior management will hold virtual one-on-one meetings with investors on November 16. Freeline focuses on developing AAV-mediated gene therapies for inherited debilitating diseases, with programs targeting Hemophilia B and Fabry disease.

Freeline Therapeutics (Nasdaq: FRLN) announced promising results from its MARVEL-1 trial for FLT190 treating Fabry disease, showing sustained α-Gal A expression for over two years in the first patient and near-normal levels in the second patient, who has been off enzyme replacement therapy for over 16 weeks. However, a case of mild myocarditis was reported. The company also provided updates on FLT201 for Gaucher disease and FLT180a for hemophilia B, with trials expected to initiate in Q1 2022. Financially, cash reserves decreased to $136.4 million, but Freeline expects to fund operations into Q1 2023.

Freeline Therapeutics (Nasdaq: FRLN), a biotechnology company focused on gene therapies for serious inherited diseases, announced the presentation of long-term data from its Phase 1/2 B-AMAZE trial on FLT180a, targeting hemophilia B. The findings will be showcased at the 63rd American Society of Hematology Annual Meeting in Atlanta from December 11-14, 2021. The session will highlight how normal Factor IX expression can prevent treatment-requiring spontaneous bleeds in patients post-therapy. This research is part of Freeline's broader commitment to innovative gene therapies.

On November 3, 2021, Freeline Therapeutics Holdings plc (Nasdaq: FRLN) announced the grant of non-statutory options to three new employees, totaling 69,800 ordinary shares and 4,250 restricted share units (RSUs). These options, with an exercise price of $3.01 per share, were approved by an independent remuneration committee and are part of the 2021 Equity Inducement Plan. The options vest over four years, with a portion vesting after the first year. Freeline is focused on developing gene therapies for inherited diseases, including Hemophilia B and Fabry disease.

Freeline Therapeutics announced the initiation of clinical trials for FLT201, targeting Gaucher disease Type 1. The FDA and the European Commission granted Orphan Drug Designation for FLT201, marking a significant milestone for the company. FLT201 uses a proprietary GCase variant to potentially improve therapeutic outcomes over current treatments. The Phase 1/2 dose-finding trial is expected to begin by year-end 2021, with clinical data anticipated in 2022. Freeline aims to provide a one-time gene therapy solution, reducing the treatment burden on patients.

Freeline Therapeutics (Nasdaq: FRLN), a clinical-stage biotechnology firm, announced its CEO, Michael Parini, will present at two upcoming virtual investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference is set for September 13, 2021, with a fireside chat available on-demand. The Morgan Stanley 19th Annual Global Healthcare Conference will take place on September 15, 2021, at 8:45 a.m. ET. Both webcasts will be accessible for 90 days on the company’s website. Freeline focuses on AAV-mediated gene therapies for inherited systemic diseases.